Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. Keeping that in mind, here are three value stocks with poor fundamentals and some alternatives you should consider instead.
Resideo (REZI)
Forward P/E Ratio: 10.9x
Resideo Technologies, Inc. (NYSE: REZI) is a manufacturer and distributor of technology-driven products and solutions for home comfort, energy management, water management, and safety and security.
Why Are We Wary of REZI?
- Incremental sales over the last five years were less profitable as its earnings per share were flat while its revenue grew
- Free cash flow margin shrank by 21.1 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- Eroding returns on capital suggest its historical profit centers are aging
At $33.63 per share, Resideo trades at 10.9x forward P/E. To fully understand why you should be careful with REZI, check out our full research report (it’s free).
Organon (OGN)
Forward P/E Ratio: 1.8x
Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women's health, Organon (NYSE:OGN) is a global healthcare company focused on improving women's health through prescription therapies, medical devices, biosimilars, and established medicines.
Why Is OGN Not Exciting?
- Sales were flat over the last five years, indicating it’s failed to expand this cycle
- Earnings per share have dipped by 12.8% annually over the past four years, which is concerning because stock prices follow EPS over the long term
- 22.6 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
Organon’s stock price of $6.29 implies a valuation ratio of 1.8x forward P/E. Check out our free in-depth research report to learn more about why OGN doesn’t pass our bar.
Peoples Bancorp (PEBO)
Forward P/B Ratio: 0.9x
Founded in 1902 in Ohio and expanding through both organic growth and acquisitions, Peoples Bancorp (NASDAQ:PEBO) is a financial holding company that provides banking, insurance, equipment leasing, and investment services to consumers and businesses.
Why Does PEBO Worry Us?
- 3.5% annual revenue growth over the last two years was slower than its banking peers
- Net interest margin shrank by 45.3 basis points (100 basis points = 1 percentage point) over the last two years, suggesting the profitability of its loan book is decreasing or the market is becoming more competitive
- Performance over the past two years shows its incremental sales were much less profitable, as its earnings per share fell by 12.4% annually
Peoples Bancorp is trading at $31.72 per share, or 0.9x forward P/B. Read our free research report to see why you should think twice about including PEBO in your portfolio.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.